EUCTR2004-003595-11-DK进行中(未招募)不适用
PeriOperative ISchemic Evaluation study - POISE
Canadian Cardiovascular Collaboration, Population Health Research Institute, McMaster University0 个研究点目标入组 10,000 人开始时间: 2005年1月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 10,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible if they are undergoing non cardiac surgery; age > 45 years, have an expected length of hospital stay > 24 hours for surgical reasons, AND fulfill any one of the following six criteria: history of coronary artery disease, peripheral vascular disease, history of stroke thought due to atherothrombotic disease, hospitalization for congestive heart failure within 3 years of randomization, undergoing major vascular surgery OR fulfill any 3 of the following 7 risk factors: undergoing high-risk type surgery (intrathoracic, intraperitoneal), any history of congestive heart failure, diabetes and currently on an oral hypoglycemic agent or insulin therapy, pre-operative serum creatinine > 175 µmol/L (>2.0 mg/dl), age > 70 years, history of transient ischemic attack, undergoing emergency/urgent surgery
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Contraindication to metoprolol including any of the following: significant bradycardia (heart rate < 50 beats per minute); second or third degree heart block without a pacemaker; asthma that has been active within the last decade (i.e. a clinical diagnosis of asthma and use of regular inhaled steroids, or beta agonists at least once per week over the period of a month, any time in the last ten years); and a history of COPD with bronchospasm on pulmonary function tests (i.e. an increase in FEV1 > 12% and of at least 200 ml, 15 minutes after inhalation of a beta 2 – agonist).
- •Clinical plan to use a beta-blocker preoperatively or during the first 30 postoperative days
- •Prior adverse reaction to a beta-blocker
- •CABG surgery with complete revascularization in the preceding 5 years and no evidence of cardiac ischemia since the CABG surgery
- •Patients undergoing low risk surgical procedures (e.g. transurethral procedures [transurethral prostatectomies (TURPs), stone baskets, etc], ophthalmologic procedures under topical or regional anesthesia [cornea transplants, cataract surgery, etc], and surgeries with limited physiological stresses [digital re-implantation, nerve repairs, etc] )
- •Concurrent use of verapamil; OR
- •Prior enrollment in this trial
研究者
相似试验
已完成
3 期
Peri-Operative ISchemic Evaluation-3 Trialvascular events1001928010023213heart failureNL-OMON48217Population Health Research Institute400
进行中(未招募)
1 期
Evaluation of strategies aiming at controlling perioperative ischemia - 3 (POISE-3)The occurrence of life-threatening, major, and critical organ bleeding in patients who are undergoing noncardiac surgery.MedDRA version: 23.1Level: LLTClassification code 10051014Term: Post procedural bleedingSystem Organ Class: 100000004863EUCTR2018-000539-29-ITHamilton Health Sciences Corporation10,000
进行中(未招募)
不适用
eriOperative ISchemic Evaluation-2 TrialEUCTR2009-018173-31-ATPopulation Health Research Institute10,000
招募中
3 期
â??Evaluation of tranexamic acid compared with placebo among patients with or at risk of heart disease undergoing surgeries not related to the heart, on bleeding and blood vessel occlusive outcomesCTRI/2019/06/019833Population Health Research Institute
进行中(未招募)
1 期
PeriOperative ISchemic Evaluation-3 (POISE-3) TrialEUCTR2018-000539-29-DKHamilton Health Sciences Corporation10,000
